Small Intestinal Ulceration

Small intestinal ulceration refers to a breach in the mucosal integrity of the duodenum, jejunum, or ileum, extending through the epithelial layer and often into the submucosa or deeper. This condition results from an imbalance between aggressive factors (gastric acid, pepsin, bile acids, pancreatic enzymes, nonsteroidal anti-inflammatory drugs, and infectious agents) and protective mucosal defenses (mucus layer, bicarbonate secretion, rich mucosal blood flow, prostaglandins, and rapid epithelial restitution). Ulcers can be acute or chronic, single or multiple, and may lead to hemorrhage, perforation, peritonitis, or stricture formation. In veterinary medicine, small intestinal ulcers are less common than gastric ulcers but carry significant morbidity and mortality, particularly when perforation occurs. The clinical presentation ranges from subtle signs of chronic blood loss to acute, life-threatening collapse due to hematochezia or perforation. Accurate diagnosis requires a combination of clinical suspicion, laboratory evaluation, imaging, and endoscopic or surgical visualization. Management focuses on addressing the underlying cause, suppressing gastric acid secretion, enhancing mucosal protection, and providing supportive care, with surgical intervention reserved for perforation or uncontrolled hemorrhage.

The etiology of small intestinal ulceration in dogs and cats is multifactorial. Primary causes include: (1) Nonsteroidal anti-inflammatory drugs (NSAIDs) such as carprofen, meloxicam, and ibuprofen, which inhibit cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and compromising mucosal blood flow and mucus production. (2) Glucocorticoids, especially at high doses, which can decrease mucosal proliferation and increase acid secretion. (3) Gastrin-secreting tumors (gastrinoma) leading to Zollinger-Ellison syndrome, characterized by severe, recurrent ulcers in the stomach and proximal duodenum due to hypergastrinemia. (4) Hepatic disease, particularly portosystemic shunts, which reduce hepatic metabolism of gastrin and histamine, increasing acid secretion. (5) Inflammatory bowel disease (IBD), including lymphocytic-plasmacytic enteritis, eosinophilic enteritis, and granulomatous enteritis, which can cause mucosal erosion and ulceration. (6) Infectious agents: canine parvovirus type 2 (CPV-2) causes severe enteritis with mucosal necrosis and ulceration; Salmonella spp., Campylobacter spp., Clostridium perfringens, and Histoplasma capsulatum can also induce ulcerative lesions. (7) Parasitic infections: hookworms (Ancylostoma caninum, Uncinaria stenocephala) attach to the mucosa and cause blood loss and ulceration; Trichuris vulpis (whipworm) can cause cecal and colonic ulcers, but small intestinal involvement is less common. (8) Neoplasia: intestinal lymphoma, adenocarcinoma, leiomyosarcoma, and mast cell tumors can ulcerate due to rapid growth and tissue invasion. (9) Foreign bodies: sharp objects or linear foreign bodies can cause mechanical trauma and pressure necrosis leading to ulceration. (10) Ischemic injury: secondary to thromboembolism, shock, or intussusception, resulting in mucosal hypoxia and necrosis. (11) Toxins: ingestion of caustic substances, heavy metals, or certain plants. (12) Idiopathic or stress-related ulcers, particularly in critically ill patients. The exact pathogenesis varies with the underlying cause, but common final pathways include disruption of the mucosal barrier, increased acid and pepsin secretion, reduced mucosal blood flow, and impaired cellular regeneration.

Small intestinal ulceration is less frequently reported than gastric ulceration in dogs and cats, but it is a significant clinical entity. In dogs, NSAID administration is a leading cause, with breeds such as Labrador Retrievers, Golden Retrievers, and German Shepherds being overrepresented due to their frequent use in sports and working roles. Gastrinoma is rare but has been reported in middle-aged to older dogs, with no strong breed predilection. Inflammatory bowel disease is common in both dogs and cats, with certain breeds like Boxers (granulomatous colitis), German Shepherds (IBD), and Siamese cats (lymphocytic-plasmacytic enteritis) being predisposed. Infectious causes, such as parvovirus, are more common in puppies under 6 months of age, especially in unvaccinated or inadequately vaccinated populations. Parasitic infections are more prevalent in young animals and those with poor hygiene or overcrowding. Neoplastic causes increase with age, with lymphoma being the most common intestinal tumor in cats and adenocarcinoma in dogs. There is no strong sex predilection for small intestinal ulceration overall, but some studies suggest a slight male predominance in dogs with gastrinoma. Geographic variation exists for infectious and parasitic causes, with histoplasmosis more common in the Mississippi River Valley and other endemic areas. The incidence of NSAID-induced ulcers has decreased with the advent of more selective COX-2 inhibitors, but they remain a common cause of gastrointestinal ulceration in dogs. Overall, the true prevalence is unknown due to underdiagnosis, as many ulcers are asymptomatic or cause only mild signs.

The pathophysiology of small intestinal ulceration involves a complex interplay of aggressive and protective factors. The intestinal mucosa is protected by a layer of mucus, bicarbonate secretion, and a rich blood supply that delivers oxygen and nutrients while removing acid and toxins. Prostaglandins, particularly PGE2, play a crucial role in maintaining mucosal integrity by stimulating mucus and bicarbonate secretion, promoting blood flow, and enhancing epithelial cell proliferation. NSAIDs inhibit COX enzymes, leading to decreased prostaglandin synthesis, which compromises these protective mechanisms. Additionally, NSAIDs can directly damage the mucosal barrier by uncoupling oxidative phosphorylation in mitochondria and increasing intestinal permeability. Glucocorticoids increase gastric acid secretion and decrease mucus production, but their role in small intestinal ulceration is less clear; they may exacerbate existing lesions or delay healing. Gastrinoma leads to hypergastrinemia, which stimulates parietal cells to secrete excessive acid, overwhelming the duodenal mucosal defenses and causing ulceration. Portosystemic shunts result in elevated blood levels of gastrin and other gut hormones due to reduced hepatic clearance, leading to increased acid secretion. Inflammatory bowel disease involves chronic infiltration of the mucosa by inflammatory cells, which release cytokines and reactive oxygen species, causing tissue damage and ulceration. Infectious agents like parvovirus directly infect and lyse intestinal crypt epithelial cells, leading to villous atrophy, crypt necrosis, and ulceration. Parasitic infections cause mechanical damage and blood loss, leading to mucosal erosion. Neoplastic infiltration disrupts normal tissue architecture and can outgrow the blood supply, causing ischemic necrosis and ulceration. Foreign bodies cause direct mechanical trauma and pressure necrosis. Ischemic injury results from reduced blood flow, leading to hypoxia, ATP depletion, and cell death. The final common pathway is a breach in the mucosal barrier, allowing luminal contents (bacteria, toxins, digestive enzymes) to enter the submucosa, triggering inflammation, hemorrhage, and potentially perforation. Perforation leads to peritonitis, which can be rapidly fatal. Chronic blood loss from ulcers can result in iron deficiency anemia and hypoproteinemia.

Predisposing factors for small intestinal ulceration include: (1) Advanced age, which is associated with decreased mucosal repair capacity and increased prevalence of neoplasia and chronic diseases. (2) Breed predispositions: Boxers are prone to histiocytic ulcerative colitis, which can extend to the small intestine; German Shepherds have a higher incidence of IBD and exocrine pancreatic insufficiency, which can alter mucosal defenses; Siamese cats are predisposed to lymphocytic-plasmacytic enteritis. (3) Concurrent diseases: chronic kidney disease, liver disease (especially portosystemic shunts), pancreatitis, and inflammatory bowel disease increase the risk. (4) Medications: NSAIDs, glucocorticoids, and some chemotherapeutic agents (e.g., doxorubicin) can cause or exacerbate ulcers. (5) Stress: critical illness, surgery, trauma, or strenuous exercise can lead to stress ulcers due to reduced mucosal blood flow and increased acid secretion. (6) Dietary factors: ingestion of foreign bodies, bones, or sharp objects can cause mechanical injury. (7) Infectious agents: parvovirus is more common in unvaccinated puppies; parasitic infections are more common in young animals with poor hygiene. (8) Immunosuppression: animals on immunosuppressive therapy or with immunodeficiency are more susceptible to infectious and neoplastic causes. (9) Endocrine disorders: hypoadrenocorticism (Addison's disease) can cause gastrointestinal signs and may predispose to ulceration. (10) Genetic factors: certain breeds may have inherent defects in mucosal barrier function or acid secretion. (11) Environmental factors: overcrowding, poor sanitation, and stress in kennels or shelters increase the risk of infectious and parasitic causes.

Clinical signs of small intestinal ulceration vary depending on the severity, location, and underlying cause. In peracute cases, especially with perforation, animals may present with acute collapse, severe abdominal pain, and shock. Acute signs include: (1) Hematemesis (vomiting of blood) or melena (dark, tarry stools) due to upper gastrointestinal bleeding; hematochezia (fresh blood in feces) may occur if the ulcer is in the distal small intestine. (2) Vomiting, which may be projectile and contain blood or bile. (3) Anorexia and weight loss. (4) Abdominal pain, often localized to the cranial abdomen, which may be evidenced by a tucked-up abdomen, restlessness, or reluctance to move. (5) Diarrhea, which may be watery or contain blood. (6) Pale mucous membranes, tachycardia, and weak pulses due to blood loss. (7) Fever, if there is secondary peritonitis. Subacute and chronic signs include: (1) Intermittent vomiting and diarrhea. (2) Progressive weight loss and poor body condition. (3) Chronic anemia and hypoproteinemia, leading to lethargy and weakness. (4) Pica or changes in appetite. (5) In cases of gastrinoma, signs may be more severe and refractory to treatment. Physical examination may reveal dehydration, pale mucous membranes, abdominal pain on palpation, and possibly a palpable mass if neoplasia is present. In cases of perforation, signs of peritonitis (fever, abdominal distension, severe pain, and shock) may be evident. It is important to note that some animals with small intestinal ulcers may be asymptomatic or show only mild, nonspecific signs, making diagnosis challenging.

Differential diagnoses for small intestinal ulceration include: (1) Gastric ulceration: can present with similar signs of vomiting and melena; differentiation requires endoscopy or imaging. (2) Inflammatory bowel disease (IBD): chronic vomiting, diarrhea, and weight loss; biopsy is needed to differentiate from ulcerative lesions. (3) Intestinal neoplasia (lymphoma, adenocarcinoma, leiomyosarcoma): may cause ulceration and obstruction; imaging and biopsy are necessary. (4) Infectious enteritis (parvovirus, salmonellosis, campylobacteriosis): acute onset of vomiting, diarrhea, and fever; fecal PCR or culture can identify the pathogen. (5) Parasitic infections (hookworms, whipworms): cause blood loss and diarrhea; fecal flotation or PCR is diagnostic. (6) Foreign body obstruction: acute vomiting and abdominal pain; imaging (radiography, ultrasound) can reveal the foreign body. (7) Intussusception: palpable abdominal mass, vomiting, and bloody diarrhea; ultrasound is diagnostic. (8) Pancreatitis: vomiting, abdominal pain, and elevated pancreatic lipase; ultrasound and serum fPLI/cPLI are helpful. (9) Hepatic disease (portosystemic shunt): may cause gastrointestinal signs and ulceration; bile acid testing and imaging are needed. (10) Hypoadrenocorticism: weakness, vomiting, diarrhea, and electrolyte abnormalities; ACTH stimulation test is diagnostic. (11) Coagulopathies (e.g., rodenticide toxicity, disseminated intravascular coagulation): can cause gastrointestinal bleeding; coagulation panel is indicated. (12) Drug-induced gastropathy: history of NSAID or corticosteroid administration. Each differential can be ruled in or out based on history, physical examination, laboratory findings, imaging, and biopsy.

The diagnostic approach to small intestinal ulceration should be systematic and stepwise. 1. Initial triage: Assess vital signs, hydration status, and cardiovascular stability. If the animal is unstable, initiate emergency stabilization (IV fluids, blood transfusion if needed) before proceeding with diagnostics. 2. History and physical examination: Obtain a thorough history, including drug administration, diet, toxin exposure, and travel history. Perform a complete physical examination, paying attention to abdominal palpation, oral mucous membranes, and evidence of pain. 3. Baseline laboratory tests: Complete blood count (CBC) to assess for anemia, leukocytosis, or thrombocytopenia; serum biochemistry profile to evaluate organ function, electrolytes, and protein levels; urinalysis to assess renal function and hydration. 4. Fecal examination: Fecal flotation, direct smear, and PCR for infectious agents (parvovirus, Salmonella, Campylobacter, Clostridium). 5. Abdominal imaging: Survey radiographs may reveal free gas (perforation), foreign bodies, or organomegaly. Abdominal ultrasound is more sensitive for detecting intestinal wall thickening, masses, and free fluid. 6. Specific biomarkers: Serum gastrin concentration if gastrinoma is suspected; canine/feline pancreatic lipase immunoreactivity (cPLI/fPLI) to rule out pancreatitis; basal cortisol or ACTH stimulation test if hypoadrenocorticism is suspected. 7. Endoscopy: Upper gastrointestinal endoscopy allows direct visualization of the duodenal mucosa and biopsy collection. It is the gold standard for diagnosing mucosal ulcers. 8. Surgical exploration: If endoscopy is not available or if perforation is suspected, exploratory laparotomy may be necessary. Full-thickness biopsies can be obtained for histopathology. 9. Histopathology: Biopsy samples should be evaluated by a veterinary pathologist to determine the underlying cause (inflammation, neoplasia, infectious agents). 10. Additional tests: If a portosystemic shunt is suspected, bile acid testing, ammonia levels, and advanced imaging (CT angiography) may be indicated. The diagnostic algorithm should be tailored to the individual case, but the above steps provide a logical progression from non-invasive to invasive testing.

Laboratory findings in small intestinal ulceration are variable and depend on the severity and chronicity of the disease. Hematology: (1) Anemia: May be regenerative (acute blood loss) or non-regenerative (chronic blood loss leading to iron deficiency). Microcytic, hypochromic anemia is characteristic of chronic iron deficiency. (2) Leukocytosis: May be present due to inflammation or infection; a left shift may indicate sepsis. (3) Thrombocytopenia: Can occur with disseminated intravascular coagulation (DIC) or bone marrow suppression. Serum biochemistry: (1) Hypoproteinemia: Due to protein-losing enteropathy (PLE) from mucosal damage; albumin and globulin may be decreased. (2) Electrolyte imbalances: Hyponatremia, hypokalemia, and metabolic alkalosis can occur with vomiting; metabolic acidosis may occur with diarrhea or shock. (3) Elevated liver enzymes: May be seen with hepatic disease or secondary to sepsis. (4) Azotemia: Prerenal due to dehydration or renal disease. (5) Hypergastrinemia: Elevated serum gastrin (>100 pg/mL) is suggestive of gastrinoma. Urinalysis: May show concentrated urine if dehydrated; proteinuria may be present with glomerular disease. Blood gas analysis: May reveal metabolic alkalosis (vomiting) or acidosis (diarrhea, shock). Specific biomarkers: (1) cPLI/fPLI: Elevated in pancreatitis, which can be a differential or concurrent condition. (2) NT-proBNP: May be elevated with cardiac disease, but not specific. (3) Troponin I: Elevated with myocardial damage, but not directly related to intestinal ulcers. (4) SDMA: Early indicator of renal dysfunction. (5) CRP: Acute phase protein, elevated with inflammation. Serology/PCR: For infectious agents (parvovirus, FeLV/FIV, histoplasmosis). Coagulation panel: Prolonged PT/aPTT may indicate rodenticide toxicity or DIC. Fecal occult blood test: Can confirm gastrointestinal bleeding, but is not specific for location.

Imaging plays a crucial role in the diagnosis and management of small intestinal ulceration. Radiography: (1) Abdominal radiographs may show a gas-filled stomach or intestines, but are often unremarkable in early cases. (2) Free gas in the abdomen (pneumoperitoneum) is a strong indicator of perforation. (3) Foreign bodies may be visible if radiopaque. (4) Loss of serosal detail may indicate peritonitis or free fluid. Ultrasonography: (1) Is the preferred imaging modality for evaluating the intestinal tract. (2) Findings may include focal or diffuse thickening of the intestinal wall, loss of normal layering, and decreased echogenicity. (3) Ulcers may appear as focal mucosal defects with hyperechoic foci (gas) or hypoechoic areas. (4) Free fluid in the abdomen may be seen with perforation. (5) Doppler ultrasound can assess blood flow to the affected segment. (6) Ultrasound-guided fine-needle aspiration of masses or thickened segments can be performed. Computed Tomography (CT): (1) Provides high-resolution cross-sectional images and is useful for detecting small lesions, masses, and lymphadenopathy. (2) CT angiography can evaluate for portosystemic shunts. (3) CT is more sensitive than radiography for detecting free gas and peritonitis. Magnetic Resonance Imaging (MRI): (1) Rarely used for intestinal imaging due to motion artifacts, but can be helpful for evaluating pelvic or perianal disease. Endoscopy: (1) Upper GI endoscopy allows direct visualization of the duodenal mucosa and is the gold standard for diagnosing ulcers. (2) Ulcers appear as well-demarcated, depressed lesions with a fibrinopurulent base. (3) Biopsies can be taken for histopathology. (4) Endoscopy can also be used for therapeutic interventions, such as hemostasis. Fluoroscopy: (1) Used for barium contrast studies to evaluate motility and filling defects, but has largely been replaced by endoscopy and ultrasound. Echocardiography: (1) Not directly useful for intestinal ulcers, but may be indicated if cardiac disease is suspected as a cause of thromboembolism.

Cytology and histopathology are essential for determining the underlying cause of small intestinal ulceration. Fine-needle aspiration (FNA) of intestinal masses or thickened segments can be performed under ultrasound guidance. Cytological findings may include: (1) Inflammatory cells (lymphocytes, plasma cells, eosinophils, neutrophils) in cases of IBD. (2) Neoplastic cells (lymphoblasts, epithelial cells with atypia) in cases of lymphoma or carcinoma. (3) Infectious organisms (Histoplasma, fungi) may be seen with special stains. Fluid analysis: If peritoneal effusion is present, abdominocentesis should be performed. The fluid may be a modified transudate or exudate, with high protein and nucleated cell counts if peritonitis is present. Cytology of the fluid may reveal bacteria and degenerate neutrophils. Histopathology: Full-thickness biopsies obtained during surgery or endoscopic biopsies are the gold standard for diagnosis. Histological features of ulceration include: (1) Loss of surface epithelium with erosion into the lamina propria or deeper. (2) Necrosis and fibrin deposition at the ulcer base. (3) Inflammatory infiltrate (neutrophils, lymphocytes, plasma cells, eosinophils) depending on the cause. (4) Granulation tissue and fibrosis in chronic ulcers. (5) Evidence of neoplasia if present. (6) Special stains (Gram, Giemsa, PAS) can identify infectious agents. (7) In cases of IBD, there is lymphocytic-plasmacytic infiltration with villous blunting and crypt hyperplasia. (8) In parvovirus infection, there is crypt necrosis and villous atrophy. Histopathology is crucial for differentiating between inflammatory, infectious, and neoplastic causes, and for guiding treatment.

Treatment of small intestinal ulceration should be tailored to the underlying cause and the severity of the clinical signs. Emergency stabilization: (1) IV fluid therapy with isotonic crystalloids (e.g., Lactated Ringer's solution) at shock doses (e.g., 60-90 mL/kg in dogs, 40-60 mL/kg in cats) for hypovolemic shock, followed by maintenance rates (e.g., 2-4 mL/kg/hr). (2) Blood transfusion if severe anemia (PCV < 20%) or hypoproteinemia (albumin < 2.0 g/dL). (3) Analgesia: Opioids such as buprenorphine (0.01-0.02 mg/kg IV/IM q8-12h) or fentanyl CRI (2-5 mcg/kg/hr) for abdominal pain. Medical therapy: (1) Gastric acid suppression: Proton pump inhibitors (PPIs) are the mainstay. Omeprazole: 1 mg/kg PO q12h or 0.7-1.5 mg/kg IV q24h. Pantoprazole: 0.7-1.0 mg/kg IV q24h. (2) H2 receptor antagonists: Famotidine: 0.5-1 mg/kg PO/IV q12h. (3) Mucosal protectants: Sucralfate: 0.5-1 g/dog PO q8h, 250-500 mg/cat PO q8h, given 30-60 minutes before meals or other medications. (4) Antiemetics: Maropitant: 1 mg/kg SC q24h or 2 mg/kg PO q24h; metoclopramide: 1-2 mg/kg/day CRI or 0.2-0.4 mg/kg PO q8h. (5) Antibiotics: Indicated if there is evidence of bacterial translocation or peritonitis. Ampicillin/sulbactam: 20 mg/kg IV q8h; metronidazole: 10-15 mg/kg IV/PO q12h. (6) Nutritional support: Early enteral nutrition is beneficial. Place a nasoesophageal or esophagostomy tube if the animal is anorexic. Use a highly digestible, low-residue diet. (7) Treatment of underlying cause: Discontinue NSAIDs or corticosteroids; treat infectious agents with appropriate antimicrobials (e.g., doxycycline for rickettsial, metronidazole for Giardia); manage IBD with immunosuppressive doses of prednisone (1-2 mg/kg/day) and other immunomodulators; surgical resection of neoplasms or foreign bodies. Surgical intervention: Indicated for perforation, uncontrolled hemorrhage, or when medical therapy fails. Surgical options include resection and anastomosis of the affected segment. Postoperative care includes continued fluid therapy, analgesia, and monitoring for complications. Prognosis depends on the underlying cause and the timeliness of intervention.

The prognosis for small intestinal ulceration varies widely depending on the etiology, severity, and presence of complications. For NSAID-induced ulcers, the prognosis is generally good if the drug is discontinued and appropriate therapy is initiated promptly; most animals recover within 1-2 weeks. However, if perforation occurs, the prognosis is guarded to poor, with mortality rates reported as high as 50-70% even with surgery. Gastrinoma carries a guarded prognosis due to the high risk of recurrence and metastasis; median survival times in dogs with gastrinoma are reported to be around 12-18 months with medical management (PPIs) and surgical debulking. Inflammatory bowel disease is a chronic condition that can be managed but not cured; many animals require long-term immunosuppressive therapy, and the prognosis is variable, with some animals achieving remission and others experiencing refractory disease. Infectious causes, such as parvovirus, have a good prognosis with aggressive supportive care, with survival rates exceeding 80% in well-managed cases. Neoplastic causes have a poor to guarded prognosis depending on the tumor type and stage; lymphoma in cats may respond to chemotherapy, with median survival times of 6-12 months, while adenocarcinoma carries a poor prognosis, with median survival times of 3-6 months after surgical resection. Negative prognostic indicators include: (1) Perforation and peritonitis. (2) Severe hypoalbuminemia (< 2.0 g/dL). (3) Presence of neoplasia. (4) Lack of response to medical therapy within 48-72 hours. (5) Concurrent diseases such as renal or hepatic failure. Overall, early diagnosis and treatment are associated with better outcomes.

Follow-up care for small intestinal ulceration is essential to monitor response to therapy and detect complications. Re-check intervals: (1) Initial re-evaluation within 3-5 days after starting treatment to assess clinical improvement and adjust medications. (2) Subsequent re-checks every 1-2 weeks until resolution of clinical signs. (3) For chronic conditions (IBD, gastrinoma), long-term monitoring every 1-3 months. Serial laboratory monitoring: (1) CBC and serum biochemistry to monitor anemia, protein levels, and electrolyte balance. (2) Fecal occult blood tests to confirm cessation of gastrointestinal bleeding. (3) Serum gastrin levels in cases of gastrinoma to assess response to therapy. Repeat imaging: (1) Abdominal ultrasound may be repeated to evaluate healing of ulcers or progression of lesions. (2) Endoscopy may be repeated if clinical signs recur or to confirm healing. Dose-titration guidelines: (1) Taper immunosuppressive drugs (e.g., prednisone) gradually over weeks to months to avoid relapse. (2) Adjust PPI doses based on clinical response; some animals may require long-term therapy. Long-term management: (1) Dietary modification: Feed a highly digestible, low-residue diet; consider adding soluble fiber (e.g., psyllium) for diarrhea. (2) Avoid NSAIDs and corticosteroids if possible; use alternative analgesics (e.g., acetaminophen is contraindicated in cats, but tramadol may be used). (3) For animals with IBD, maintain immunosuppressive therapy at the lowest effective dose. (4) For animals with portosystemic shunts, consider surgical ligation or medical management with lactulose and a low-protein diet. (5) Monitor for signs of recurrence, such as vomiting, diarrhea, or melena, and seek veterinary attention promptly. Client education is crucial to ensure compliance with medication and dietary recommendations.

Pearls: (1) Always consider NSAID toxicity in any dog or cat presenting with vomiting, melena, or anemia; ask about recent drug administration. (2) Sucralfate should be given on an empty stomach, at least 1 hour before or 2 hours after meals and other medications, to maximize its mucosal protective effect. (3) In cases of suspected perforation, obtain abdominal radiographs to look for free gas; if present, emergency surgery is indicated. (4) Use a combination of a PPI and sucralfate for severe ulcers; PPIs are more effective than H2 blockers for acid suppression. (5) In cats, be cautious with metronidazole dosing; high doses can cause neurotoxicity. (6) Early enteral nutrition is beneficial; consider placing a feeding tube if the animal is anorexic for more than 24 hours. (7) In cases of chronic blood loss, check iron status and consider iron supplementation. (8) Always perform a thorough search for an underlying cause; treating the ulcer without addressing the cause will lead to recurrence. Pitfalls: (1) Do not use corticosteroids in animals with suspected or confirmed ulcers, as they can worsen the condition. (2) Avoid using NSAIDs in animals with renal disease, hepatic disease, or dehydration. (3) Do not delay surgery if perforation is suspected; waiting can be fatal. (4) Do not rely solely on radiographs to rule out perforation; ultrasound or CT may be more sensitive. (5) Do not use metoclopramide in animals with intestinal obstruction, as it can cause severe cramping. (6) Do not administer oral medications immediately after sucralfate; allow at least 1 hour between doses. (7) Do not forget to monitor for complications such as peritonitis, sepsis, and DIC in critically ill animals. (8) Do not assume that all ulcers are benign; always obtain biopsies to rule out neoplasia.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for small intestinal ulceration: (1) Proton Pump Inhibitors: Omeprazole: Dogs: 0.5-1 mg/kg PO q12h; Cats: 0.7-1 mg/kg PO q12h. For IV use: 0.7-1 mg/kg IV q24h (dogs). Pantoprazole: Dogs: 0.7-1 mg/kg IV q24h. (2) H2 Receptor Antagonists: Famotidine: Dogs: 0.5-1 mg/kg PO/IV q12h; Cats: 0.5-1 mg/kg PO/IV q12h. (3) Mucosal Protectants: Sucralfate: Dogs: 0.5-1 g PO q8h; Cats: 250-500 mg PO q8h. Administer as a slurry in water, 30-60 minutes before meals. (4) Antiemetics: Maropitant: Dogs: 1 mg/kg SC q24h or 2 mg/kg PO q24h; Cats: 1 mg/kg SC q24h or 2 mg/kg PO q24h. Metoclopramide: Dogs: 0.2-0.4 mg/kg PO q8h or 1-2 mg/kg/day CRI; Cats: 0.2-0.4 mg/kg PO q8h or 1-2 mg/kg/day CRI. (5) Antibiotics: Ampicillin/sulbactam: Dogs: 20 mg/kg IV q8h; Cats: 20 mg/kg IV q8h. Metronidazole: Dogs: 10-15 mg/kg IV/PO q12h; Cats: 7.5-10 mg/kg IV/PO q12h. (6) Analgesics: Buprenorphine: Dogs: 0.01-0.02 mg/kg IV/IM q8-12h; Cats: 0.01-0.02 mg/kg IV/IM q8-12h. Fentanyl CRI: Dogs: 2-5 mcg/kg/hr IV; Cats: 1-2 mcg/kg/hr IV. (7) Immunosuppressants (for IBD): Prednisone: Dogs: 1-2 mg/kg PO q24h, then taper; Cats: 1-2 mg/kg PO q24h, then taper. Cyclosporine: Dogs: 5 mg/kg PO q24h; Cats: 5 mg/kg PO q24h. (8) Iron supplementation: Ferrous sulfate: Dogs: 100-300 mg/dog PO q24h; Cats: 50-100 mg/cat PO q24h. (9) Gastroprotectants: Misoprostol: Dogs: 2-5 mcg/kg PO q8h; Cats: not commonly used. (10) For gastrinoma: Omeprazole at higher doses (1-2 mg/kg PO q12h) may be needed. Always adjust dosages for renal or hepatic impairment, and monitor for adverse effects. Drug interactions: PPIs may increase the absorption of certain drugs; sucralfate can bind to other medications, so separate administration times.

Evidence-based literature on small intestinal ulceration in dogs and cats is limited compared to gastric ulcers, but several key studies and consensus guidelines provide guidance. (1) NSAID-induced gastrointestinal ulceration: A landmark study by Lascelles et al. (2005) evaluated the efficacy of misoprostol in preventing NSAID-induced ulcers in dogs, showing that misoprostol reduced the incidence of duodenal ulcers. (2) ACVIM consensus statement on NSAID use in dogs (2013) recommends using the lowest effective dose, avoiding concurrent corticosteroids, and considering gastroprotectants in high-risk animals. (3) Gastrinoma: A retrospective study by Hughes et al. (2010) reported that dogs with gastrinoma had a median survival of 12 months with medical management, and surgical resection improved outcomes. (4) Inflammatory bowel disease: The ACVIM consensus statement on IBD in dogs and cats (2010) recommends a stepwise approach to diagnosis and treatment, including dietary trials, antibiotics, and immunosuppressive therapy. (5) Parvovirus: A study by Prittie (2004) demonstrated that early enteral nutrition improved outcomes in dogs with parvovirus, reducing hospitalization time. (6) Perforation: A retrospective study by Gaschen et al. (2003) found that dogs with gastrointestinal perforation had a mortality rate of 50%, and early surgical intervention was associated with better survival. (7) Sucralfate: A study by Neiger et al. (2000) showed that sucralfate was effective in healing gastric ulcers in dogs, but its efficacy in small intestinal ulcers is less well-documented. (8) Proton pump inhibitors: A study by Tolbert et al. (2011) demonstrated that omeprazole was more effective than famotidine in increasing gastric pH in dogs. (9) Probiotics: Limited evidence supports the use of probiotics in managing IBD, but they may be beneficial as adjunctive therapy. (10) Future directions: Research is needed to evaluate the role of the microbiome in ulcer pathogenesis and the efficacy of novel therapies such as platelet-rich plasma and stem cell therapy. Overall, the evidence supports a multimodal approach to diagnosis and treatment, with emphasis on identifying and addressing the underlying cause.